TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from LAVA Therapeutics ( (LVTX) ).
On October 2, 2025, LAVA Therapeutics and XOMA Royalty Corporation announced the extension of the tender offer expiration to purchase all outstanding shares of LAVA. Initially set to expire on October 3, 2025, the offer is now extended to October 17, 2025. The acquisition is expected to close in the fourth quarter of 2025, subject to customary conditions, with LAVA shareholders supporting the offer. The transaction aims to result in XOMA Royalty acquiring 100% of LAVA’s shares, with implications for LAVA’s business operations and shareholder value.
The most recent analyst rating on (LVTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on LAVA Therapeutics stock, see the LVTX Stock Forecast page.
Spark’s Take on LVTX Stock
According to Spark, TipRanks’ AI Analyst, LVTX is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by negative profitability and cash flow challenges. Technical analysis provides some positive momentum, but the valuation remains unattractive due to ongoing losses. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on LVTX stock, click here.
More about LAVA Therapeutics
LAVA Therapeutics N.V. is a biopharmaceutical company that develops clinical-stage bispecific gamma delta T cell engagers using its proprietary Gammabody® platform. Their notable partnerships include collaborations with Johnson & Johnson and Pfizer, targeting hematologic cancers and solid tumors respectively.
Average Trading Volume: 217,165
Technical Sentiment Signal: Hold
Current Market Cap: $40.51M
For an in-depth examination of LVTX stock, go to TipRanks’ Overview page.